Cogent Biosciences (COGT) Short-term Investments (2017 - 2026)

Cogent Biosciences' Short-term Investments history runs 8 years deep, the most recent figure standing at $625.2 million for Q1 2026.

• In Q1 2026, Short-term Investments rose 422.46% year-over-year to $625.2 million; the TTM figure through Mar 2026 stood at $625.2 million (up 422.46% YoY), while the FY2025 annual figure was $588.8 million, up 211.65% from the prior year.
• Short-term Investments was $625.2 million for Q1 2026 at Cogent Biosciences, up from $588.8 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $625.2 million in Q1 2026 to a low of $1.3 million in Q2 2022.
• Historically, Short-term Investments has averaged $204.7 million across 5 years, with a median of $190.6 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Short-term Investments jumped 17425.02% in 2024, then plunged 59.91% in 2025.
• A 5-year view of Short-term Investments shows it stood at $119.4 million in 2022, then jumped by 77.97% to $212.5 million in 2023, then decreased by 11.09% to $188.9 million in 2024, then surged by 211.65% to $588.8 million in 2025, then increased by 6.19% to $625.2 million in 2026.
• The last three Short-term Investments figures came in at $625.2 million (Q1 2026), $588.8 million (Q4 2025), and $265.6 million (Q3 2025), per Business Quant data.